Breakthrough Cancer Pain Clinical Trial
Official title:
Characterisation and Epidemiology of Breakthrough Cancer Pain in Spain
The purpose of this study is to determine the prevalence of breakthrough cancer pain and characterize breakthrough cancer pain in an unselected, representative cohort of cancer outpatients with or without pain who attend consultations.
This study has been designed as a non-interventional, non post-authorization,
cross-sectional, epidemiological study to determine the prevalence of breakthrough cancer
pain and characterize breakthrough cancer pain in an non-selected, representative cohort of
cancer outpatients with or without pain.
The study enrolled 3765 patients. This multicenter trial will be conducted in Spain. Data
from participants will be collected through questionnaire and medical history in a single
visit (up to 1 month).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01946555 -
Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain
|
N/A | |
| Recruiting |
NCT01698645 -
Patient Satisfaction and Quality of Life Impact - PecFent®
|
N/A | |
| Recruiting |
NCT01693328 -
Patient Satisfaction and Quality of Life Impact - PecFent®
|
N/A | |
| Completed |
NCT01936636 -
Observational Registry Study of Quality of Life When Treating BTcP With Abstral
|
N/A | |
| Completed |
NCT03669263 -
A Dose Titration Study of Fentanyl Buccal Soluble Film for Breakthrough Cancer Pain in Taiwan
|
N/A | |
| Recruiting |
NCT03564548 -
Inhaled Cannabinoids Versus Immediate-release Oral Opioids for the Management of Breakthrough Cancer Pain
|
Phase 2 | |
| Not yet recruiting |
NCT04713189 -
Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With Breakthrough Cancer Pain
|
Phase 1/Phase 2 | |
| Completed |
NCT03895762 -
Observational Study of Efficacy, Safety and Tolerability of Fentanyl in Korean Cancer Patients
|
||
| Terminated |
NCT01439919 -
A Clinical Trial to Assess the Clinical Benefit of SSR411298 as Adjunctive Treatment for Persistent Cancer Pain
|
Phase 2 | |
| Completed |
NCT01045603 -
Instanyl® Non-Interventional Study
|
N/A | |
| Recruiting |
NCT00822614 -
Safety of Fentanyl TAIFUN Treatment
|
Phase 3 | |
| Terminated |
NCT04468490 -
Treatment of Breakthrough Cancer Pain According to European Guidelines
|